Imperial College London
Portrait Picture

MrMikaelSodergren

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Hepatopancreatobiliary Surgery
 
 
 
//

Contact

 

m.sodergren

 
 
//

Location

 

BN2/13Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Olsson:2023:10.1080/17512433.2023.2183841,
author = {Olsson, F and Erridge, S and Tait, J and Holvey, C and Coomber, R and Beri, S and Hoare, J and Khan, S and Weatherall, MW and Platt, M and Rucker, JJ and Sodergren, MH},
doi = {10.1080/17512433.2023.2183841},
journal = {Expert Review of Clinical Pharmacology},
pages = {257--266},
title = {An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry.},
url = {http://dx.doi.org/10.1080/17512433.2023.2183841},
volume = {16},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: There is a paucity of high-quality data on patient outcomes and safety after initiating treatment with cannabis-based medicinal products (CBMPs). The aim of this study was to assess the clinical outcomes and safety of CBMPs by analyzing patient-reported outcome measures and adverse events across a broad spectrum of chronic conditions. RESEARCH DESIGN AND METHODS: This study analyzed patients enrolled in the UK Medical Cannabis Registry. Participants completed the EQ-5D-5L to assess health-related quality of life, Generalized Anxiety Disorder-7 (GAD-7) questionnaire to measure anxiety severity, and the Single-item Sleep Quality Scale (SQS) to rate sleep quality at baseline and follow-up after 1, 3, 6, and 12 months. RESULTS: A total of 2833 participants met inclusion criteria. The EQ-5D-5L index value, GAD-7, and SQS all improved at each follow-up (p < 0.001). There was no difference in EQ-5D-5L index values between former or current illicit cannabis consumers and naïve patients (p > 0.050). Adverse events were reported by 474 (16.73%) participants. CONCLUSIONS: This study suggests that CBMPs are associated with an improvement in health-related quality of life in UK patients with chronic diseases. Treatment was tolerated well by most participants, but adverse events were more common in female and cannabis-naïve patients.
AU  - Olsson,F
AU  - Erridge,S
AU  - Tait,J
AU  - Holvey,C
AU  - Coomber,R
AU  - Beri,S
AU  - Hoare,J
AU  - Khan,S
AU  - Weatherall,MW
AU  - Platt,M
AU  - Rucker,JJ
AU  - Sodergren,MH
DO  - 10.1080/17512433.2023.2183841
EP  - 266
PY  - 2023///
SN  - 1751-2433
SP  - 257
TI  - An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry.
T2  - Expert Review of Clinical Pharmacology
UR  - http://dx.doi.org/10.1080/17512433.2023.2183841
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36848456
UR  - https://www.tandfonline.com/doi/full/10.1080/17512433.2023.2183841
UR  - http://hdl.handle.net/10044/1/103614
VL  - 16
ER  -
Download